EFFICACY AND SAFETY OF LUBIPROSTONE FOR FUNCTIONAL CONSTIPATION IN CHILDREN: A SYSTEMATIC REVIEW
DOI:
https://doi.org/10.69598/tbps.18.2.81-91Keywords:
pediatric functional constipation, lubiprostone, spontaneous bowel movement, serious adverse eventsAbstract
Pediatric functional constipation (PFC) is an important gastrointestinal disease in children. Oral and rectal laxatives have been recommended for treating PFC; however, almost half of the patients did not fully recover after 6 – 12 months of treatment. Lubiprostone is an alternative to treat PFC. However, the efficacy and safety of lubiprostone have not been summarized. This study aimed to summarize the efficacy and safety of lubiprostone for PFC. A systemic review was conducted in PubMed, Embase®, and Cochrane CENTRAL from their inception to August 2022. Studies examining the efficacy or safety of lubiprostone compared to placebo or different dosages of lubiprostone were eligible. The primary efficacy outcome was the number of responders according to spontaneous bowel movement (SBM), while the serious adverse event was the primary safety outcome. A qualitative summary was performed to summarize the evidence. A total of three articles with 1,264 patients met the inclusion criteria. Of those, one article was a randomized controlled trial (RCT) with an open-label, long-term extension and two studies were quasi-experimental. All included studies reported serious adverse events but only two studies reported SBM. The RCT indicated that 12 micrograms of lubiprostone twice daily (BID) or 24 µg BID had no statistical difference in terms of treatment response than the placebo (relative risk [RR]= 1.32; 95% confidence interval (CI) 0.89 to 10.97, p=0.22). However, when sub-grouped, lubiprostone 12 µg BID had a higher chance of being responsive than the placebo (RR= 1.89 [1.19 to 3.00], p=0.007), while lubiprostone 24 µg BID did not have a higher chance of being response than the placebo (RR= 1.12 [0.73 to 1.72], p=0.60). A non-RCT study demonstrated significant improvement of average SBM from the baseline for lubiprostone 12 µg once daily (OD), 12 µg BID, and 24 µg BID at week 4, however no significant difference among the doses was observed. No difference in serious adverse events between lubiprostone and the placebo was found. In conclusion, lubiprostone showed potential efficacy for treating children with functional constipation without any serious adverse events.
References
Leung AK, Hon KL. Paediatrics: how to manage functional constipation. Drugs Context. 2021;10:2020-11-2.
Koppen IJN, Vriesman MH, Saps M, Rajindrajith S, Shi X, van Etten-Jamaludin FS, et al. Prevalence of functional defecation disorders in children: a systematic review and meta-analysis. J Pediatr. 2018;198:121-30.
LeLeiko NS, Mayer-Brown S, Cerezo C, Plante W. Constipation. Pediatr Rev. 2020;41(8):379-92.
Zeevenhooven J, Koppen IJ, Benninga MA. The new Rome IV criteria for functional gastrointestinal disorders in infants and toddlers. Pediatr Gastroenterol Hepatol Nutr. 2017;20(1):1-13.
Levy EI, Lemmens R, Vandenplas Y, Devreker T. Functional constipation in children: challenges and solutions. Pediatric Health Med Ther. 2017;8:19-27.
Mulhem E, Khondoker F, Kandiah S. Constipation in children and adolescents: evaluation and treatment. Am Fam Physician. 2022;105(5):469-78.
Rajindrajith S, Devanarayana NM. Constipation in children: novel insight into epidemiology, pathophysiology and management. J Neurogastroenterol Motil. 2011;17(1):35-47.
Poddar U. Approach to constipation in children. Indian Pediatr. 2016;53:319-27.
Hyams JS, Di Lorenzo C, Saps M, Shulman RJ, Staiano A, van Tilburg M. Functional disorders: Children and Adolescents. Gastroenterol. 2016;150:1456-68.
Tabbers MM, DiLorenzo C, Berger MY, Faure C, Langendam MW, Nurko S, et al. Evaluation and treatment of functional constipation in infants and children: evidence-based recommendations from ESPGHAN and NASPGHAN. J Pediatr Gastroenterol Nutr. 2014;58(2):258-74.
Koppen IJN, Lammers LA, Benninga MA, Tabbers MM. Management of functional constipation in children: therapy in practice. Pediatr Drugs. 2015;17(5):349-60.
Rao SSC, Brenner DM. Efficacy and safety of over-the-counter therapies for chronic constipation: an updated systematic review. Am J Gastroenterol. 2021;116(6):1156-81.
Nurko S, Zimmerman LA. Evaluation and treatment of constipation in children and adolescents. Am Fam Physician. 2014;90(2):82-90.
Pijpers MAM, Bongers MEJ, Benninga MA, Berger MY. Functional constipation in children: a systematic review on prognosis and predictive factors. J Pediatr Gastroenterol Nutr. 2010;50(3).
Lacy BE, Levy LC. Lubiprostone: a novel treatment for chronic constipation. Clin Interv Aging. 2008;3(2):357-64.
Lacy BE, Hussain Zh Fau - Mearin F, Mearin F. Treatment for constipation: new and old pharmacological strategies. Neurogastroenterol Motil. 2014;26(6):749-63.
Lembo AJ, Johanson JF, Parkman HP, Rao SS, Miner PB Jr, Ueno R. Long-term safety and effectiveness of lubiprostone, a chloride channel (ClC-2) activator, in patients with chronic idiopathic constipation. Dig Dis Sci. 2011;56(9):2639-45.
Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:14898.
Sterne JA, Hernan MA, Reeves BC, Savovic J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.
Benninga MA, Hussain SZ, Sood MR, Nurko S, Hyman P, Clifford RA, et al. Lubiprostone for pediatric functional constipation: randomized, controlled, double-blind study with long-term extension. Clin Gastroenterol Hepatol. 2022;20(3):602‐5.
Hussain SZ, Labrum B, Mareya S, Stripling S, Clifford R. Safety of lubiprostone in pediatric patients with functional constipation: a nonrandomized, open-label trial. J Pediatr Gastroenterol Nutr. 2021;73(5):572-8.
Hyman PE, Di Lorenzo C, Prestridge LL, Youssef NN, Ueno R. Lubiprostone for the treatment of functional constipation in children. J Pediatric Gastroenterol Nutr. 2014;58(3):283-91.
McKeage K, Plosker GL, Siddiqui MA. Lubiprostone. Drugs. 2006;66(6):873-9.
Boutron I, Page MJ, Higgins JPT, Altman DG, Lundh A, Hrobjartsson A. Chapter 7: Considering bias and conflicts of interest among the included studies. 2022. In: Cochrane Handbook for Systematic Reviews of Interventions version 63 (updated February 2022) [Internet]. Cochrane. Available from: www.training.cochrane.org/handbook.
Fukudo S, Hongo M, Kaneko H, Takano M, Ueno R. Lubiprostone increases spontaneous bowel movement frequency and quality of life in patients with chronic idiopathic constipation. Clin Gastroenterol Hepatol. 2015;13(2):294-301.
Fukudo S, Hongo M, Kaneko H, Ueno R. Efficacy and safety of oral lubiprostone in constipated patients with or without irritable bowel syndrome: a randomized, placebo-controlled and dose-finding study. Neurogastroenterol Motil. 2011;23(6):544-e205.
Li F, Fu T, Tong WD, Liu BH, Li CX, Gao Y, et al. Lubiprostone Is Effective in the treatment of chronic idiopathic constipation and irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc. 2016;91(4):456-68.
Mugie SM, Korczowski B, Bodi P, Green A, Kerstens R, Ausma J, et al. Prucalopride is no more effective than placebo for children with functional constipation. Gastroenterology. 2014;147(6):1285-95.
Johanson JF, Ueno R. Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety. Aliment Pharmacol Ther. 2007;25(11):1351-61.
Downloads
Published
How to Cite
Issue
Section
License
All articles published and information contained in this journal such as text, graphics, logos and images is copyrighted by and proprietary to the Thai Bulletin of Pharmaceutical Sciences, and may not be reproduced in whole or in part by persons, organizations, or corporations other than the Thai Bulletin of Pharmaceutical Sciences and the authors without prior written permission.
